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Abstract
Background:  The  minor  BCR-ABL  (e1;a2)  transcript  oncogene  is  the  most  common  genetic  alter-
ation in  adults  with  acute  lymphoblastic  leukaemia  (ALL).  It  is  associated  with  a  poor  prognosis.
Aim: To  determine  the  frequency  of  minor  BCR-ABL  (e1;a2)  transcript  oncogene  expression  in
ALL patients  in  Mexico.
Material  and  methods:  A  cohort  of  411  patients  with  de  novo  ALL  were  tested  for  the  oncogene
using reverse  transcription  polymerase  chain  reaction  (RT-PCR).
Results:  The  oncogene  was  found  in  14%  (n  =  57)  of  the  study  population.  Mean  age  was  29  years,
and 53%  were  male.  Median  leucocyte  count  was  53  ×  103 l.
Conclusion:  Prevalence  of  BCR-ABL  expression  by  RT-PCR  has  not  previously  been  reported  in
Mexico. Our  laboratory  found  a  higher  prevalence  than  that  reported  in  Latin-American  series,
but lower  than  that  reported  for  the  European  population.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Published  by  Masson  Doyma  México
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PALABRAS  CLAVE
Leucemia  aguda
linfóblastica;
Cromosoma
Philadelphia;
Oncogén  BCR-ABL
Frecuencia  del  oncogén  BCR-ABL  (e1;a2) rompimiento  menor  en  población  mexicana
con  leucemia  linfóblastica  aguda  del  adulto
Resumen
Introducción:  El  oncogén  BCR-ABL  (e1;a2)  rompimiento  menor  constituye  la  alteración  de  mayor
frecuencia en  la  leucemia  aguda  linfóblastica  (LAL)  del  adulto.  Su  presencia  se  asocia  con
pronóstico  adverso.
Objetivo:  Determinar  la  frecuencia  de  la  expresión  del  oncogén  BCR-ABL  (e1;a2)  en  portadores
de LAL  en  México.
Material  y  métodos:  Se  estudiaron  411  pacientes  con  diagnóstico  de  LAL  de  novo  para  la
búsqueda del  oncogén  mediante  Reacción  de  cadena  de  polimerasa  por  Punto  ﬁnal  (RT-PCR).
Resultados:  El  14%  (n  =  57)  de  la  población  estudiada  presentó  expresión  positiva.  La  edad
promedio fue  29  an˜os,  el  53%  correspondió  al  sexo  masculino,  la  mediana  de  leucocitos  fue
53 ×  103 l.
Conclusión:  En  México  no  hay  reportes  de  la  frecuencia  de  expresión  de  BCR-ABL  por  RT-PCR,
nuestro laboratorio  encontró  una  frecuencia  mayor  que  lo  reportado  en  las  series  Latino-
Americanas  y  menor  a  lo  reportado  para  población  europea.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Publicado  por  Masson  Doyma  México
S.A. Todos  los  derechos  reservados.
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cute  lymphoblastic  leukaemia  (ALL)  is  one  of  the  most
ommon  types  of  cancer  found  in  Mexico,  with  an  aver-
ge  incidence  of  5  cases  per  100,000  inhabitants.1 On
verage,  70  new  cases  of  ALL  are  admitted  to  the  Haema-
ology  Department  of  the  General  Hospital  of  Mexico  each
ear.  Several  cytogenetic  abnormalities  are  involved  in  the
evelopment  of  this  type  of  cancer.  The  t(9;22)  (q34;q11)
ranslocation,  known  as  the  Philadelphia  chromosome  or  Ph
ives  rise  to  the  BCR-ABL  fusion  transcript.  This  transcript,
ogether  with  abnormalities  such  as  t(4:11),  is  associated
ith  an  adverse  prognosis.2 Incidence  of  this  gene  varies;
eports  suggest  it  to  be  5%  in  the  paediatric  population,3--5
nd  25--50%  in  adults.6--9 The  minor  BCR-ABL  transcript  codes
or  a  chimeric  protein  (190  kDa)  with  tyrosine  kinase  activ-
ty,  which  is  implicated  in  both  the  activation  of  various  cell
ignalling  pathways  (RAS-GTP)  and  cell  apoptosis  (PI3K).10--13
he  BCR-ABL  transcript  has  been  associated  with  an  adverse
rognosis  in  most  international  studies.14 The  introduction
f  therapies  that  act  on  speciﬁc  molecular  targets,  such
s  BCR-ABL  tyrosine  kinase  (TK)  inhibitors  (Glivec©, Novar-
is)  has  improved  overall  survival  rates  when  compared  to
raditional  chemotherapy.  There  are  various  methods  for
solating  the  BCR-ABL  transcript,  the  most  common  being
onventional  karyotyping,  ﬂuorescent  in  situ  hybridization
FISH),  and  polymerase  chain  reaction.15--17 In  Mexico,  the
hiladelphia  chromosome  is  found  in  around  3.8%  of  the
aediatric  population18 and  16.7%  of  adults,19 isolated  by
everse  transcription  polymerase  chain  reaction  (RT-PCR)
nd  conventional  cytogenetics,  respectively.  In  our  labora-
ory,  we  amplify  the  BCR-ABL  fusion  transcript  by  means
f  RT-PCR,  and  perform  around  60  tests  on  ALL  patients
ach  year.  In  this  study,  we  describe  the  frequency  of  minor
CR-ABL  expression  in  ALL  patients  compared  with  the  inter-
ational  literature.
f
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paterials and methods
n  experimental,  prospective,  longitudinal  study  conducted
rom  February  2000  to  January  2010  in  the  molecular  biol-
gy  laboratory  of  the  Haematology  Department.  The  study
as  approved  by  the  institution’s  independent  ethics  com-
ittees.  Male  and  female  patients  with  de  novo  diagnosis
f  ALL  that  agreed  to  give  peripheral  blood  samples  after
aving  signed  the  informed  consent  form  were  included
n  the  study.  ALL  was  diagnosed  in  accordance  with  the
rench--American--British  (FAB)  classiﬁcation  systems,  with
he  help  of  immunophenotyping  and  cytochemistry  assays.
linical  data  were  sourced  from  the  patient’s  medical
ecords  (Table  1).
ethodology
eukaemia  cells
one  marrow  samples  were  collected  from  ALL  patients
hat  had  signed  the  informed  consent  form.  Samples
ere  collected  in  heparinized  tubes  containing  Lymphoprep
Nycomed  Pharma  AS,  Oslo,  Norway)  and  centrifuged  to
btain  mononuclear  cells.
everse  transcription  polymerase  chain  reaction
RT-PCR)
otal-cell  RNA  was  isolated  with  Trizol  (Life  Technologies,
aisley,  UK),  and  1  g of  RNA  was  used  for  cDNA  synthesis  by
eans  of  MMLV  (Life  Technologies,  Paisley,  UK).  The  CMLB
rimers  5′ATCTCCACTGGCCACAAAATCATACA3′.
ALLA  5  AGATCTGGCCCAACGATGGCGAGGGC3  were  used
or  PCR  ampliﬁcation.  Results  were  validated  by  sequencing
wo  positive  samples  (ABI  PRISM  3100,  Applied  Biosystem,
an  Francisco,  USA).  Each  cDNA  was  tested  by  PCR  using
rimers  speciﬁc  for  the  constituent  ˇ2 microglobulin  gene.
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Table  1  General  clinical  characteristics  of  patients  with
acute lymphoblastic  leukaemia.
Characteristics  BCR-ABL
Negative
N  (%)
Positive
N  (%)
Total
patients  =  411
354  (86.13)  57  (13.86)
Sex
Men 194  (54.8) 30  (53)
Women  160  (45.2)  27  (47)
Median
(range)
Median
(range)
Median  age  (years)  29  (16--62)  25  (18--56)
Laboratory  tests
Baseline  leucocyte
count  (×103/l)
55.9  (0.7--789)  54  (1.2--207)
Haemoglobin  (g/dl)  7.18  (4--10.9)  7.05  (5.4--11.5)
Platelets  (×103/l)  53  (0.88--388)  45  (2--432)
N  (%)  N  (%)
FAB  classiﬁcation
L1  7  (2)  0  (0)
L2 347  (98)  57  (100)
Immunophenotype
B-cell 111  (81.6)  12  (100)
T-cell 25  (18.3)  0  (0)
M 1 2 3 4 5 6 7
M 10
397 pb
196 pb
397 pb
196 pb
The top sequence shows the constituent β2 microglobulin gene with an amplified
fragment of 397 pb. The lower sequence shows BCR-ABL expression amplified in a
fragment of 196 pb.
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lNervous  system  inﬁltration  7  (2)  0  (0)
PCR  cycles  of  1  min  94 ◦C,  1  min  55 ◦C,  1  min  72 ◦C  were
repeated  35  times.  The  PCR  products  were  stained  with
ethidium  bromide  and  visualized  in  a  1.5%  agarose  gel.
Results
Patient  characteristics
A  total  of  411  patients  with  a  mean  age  of  29  years  (range
16--62)  were  studied.  By  morphology,  most  (n  =  98%)  pre-
sented  acute  lymphoblastic  leukaemia  (ALL-L2),  with  81.6%
corresponding  to  the  B-cell  immunophenotype.  Only  2%
showed  central  nervous  system  inﬁltration  at  diagnosis.
Expression  of  the  minor  BCR-ABL  oncogene
All  411  de  novo  ALL  cases  were  studied  for  BCR-ABL  onco-
gene  expression.  RNA  quality  was  evaluated  by  ampliﬁcation
of  the  constituent  ˇ2 microglobulin  gene,  which  ampliﬁes  a
fragment  of  397  bp  by  RT-PCR.  BCR-ABL  was  isolated  in  57
patients,  amplifying  a  fragment  of  196  bp.  This  represents
13.8%  of  the  study  population.Mean  age  of  the  57  BCR-ABL-positive  patients  was  25
years  (range  18--56);  53%  (n  =  30)  were  men,  and  47%
(n  =  27)  were  women.  Mean  leucocyte  count  at  diagnosis  was
54  ×  103/l  (range  1.2--207  ×  103/l).  All  (100%)  patients
o
g
t
tFigure  1  BCR-ABL  expression  in  patients  with  ALL.
ere  of  the  B-cell  immunophenotype,  and  none  showed  cen-
ral  nervous  system  involvement  (Fig.  1).
iscussion
n  this  study,  we  evaluated  the  prevalence  of  the  BCR-ABL
ranscript  fusion  (e1;a2) in  a  population  of  ALL  patients  in
exico  using  reverse  transcription  polymerase  chain  reac-
ion  (RT-PCR).  This  technique  has  been  used  since  the  1990s
y  various  international  groups  in  both  the  diagnosis  and
ollow-up  or  ALL  Ph+.  The  ﬁrst  studies  in  RT-PCR  reported  a
revalence  of  the  minor  BCR-ABL  transcript  of  50%,  with  no
ifference  in  either  prognosis  or  clinical  presentation.20,21
esearchers  in  the  GIMEMA  0496  trial  reported  a  preva-
ence  of  minor  vs.  major  breakpoint  of  58.5%  and  41.5%,
espectively.22 Prevalence  continues  to  vary  across  Latin
merica,  ranging  from  5.7%  in  adults  and  between  2.3%
nd  2.7%  in  the  paediatric  population.22--24 Prevalence  in
LL  patients  in  the  US  is  estimated  at  19%,25 and  from  25%
o  39%  in  Asia  (Table  2).26--29 Very  few  studies  in  BCR-ABL
revalence  in  children  have  been  conducted  in  Mexico,  and
one  in  adults.  In  our  laboratory,  we  found  prevalence  to
e  greater  than  that  reported  for  Latin  America,  and  lower
han  that  reported  for  the  American  and  European  pop-
lation.  These  discrepancies  could  be  due  to  the  genetic
iversity  of  the  Latin  American  population.30 Nowadays,  it
s  particularly  important  to  isolate  the  BCR-ABL  transcript
n  ALL  patients  due  to  the  potential  beneﬁts  of  tyro-
ine  kinase  (TK)  inhibitors,  such  as  Imatinib,  nolotinib,  or
asatinib.31--34
Research  suggests  that  the  combination  of  BCR-ABL  and
K  inhibitor  therapy  reverses  the  disease  by  providing  a
peciﬁc  molecular  target.  In  contrast  to  previous  inter-
retations,  this  marker  is  now  thought  to  indicate  a  good
rognosis.  In  conclusion,  ALL  is  one  of  the  most  common
alignancies  seen  in  the  Haematology  Department.  Isola-
ion  of  BCR-ABL  in  ALL  patients  is  of  primordial  importance,
articularly  in  view  of  the  potential  action  of  tyrosine  kinase
nhibitors.35--37 Advances  in  molecular  biology,  such  as  real
ime  PCR,  will  allow  clinicians  to  monitor  BCR-ABL  transcript
evels  more  closely.  An  understanding  of  the  prevalence
f  this  fusion  gene  in  the  Mexican  population  will  give
reater  insight  into  ALL,  improve  management  and  moni-
oring  of  the  disease,  and  introduce  more  speciﬁc  TK-based
herapy.
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Table  2  Prevalence  of  the  BCR-ABL  Ph+  oncogene  worldwide,  by  cytogenetic  and  RT-PCR  testing.
Region  Patients  N  Prevalence  (%)  Testing  technique  Reference
Asia
China  Adults  389  28.3  RT-PCR  Li  et  al.27
China  Adults  137  37  RT-PCR  Bao  et  al.28
Malaysia  Children  299  7.8  RT-PCR  Arifﬁn  et  al.29
Japan  Adults  285  22  Cytogenetic  Takeuchi  et  al.34
India  Adults  and  children  33  24  children19  adults  RT-PCR  Gurbuxani  et  al.30
US
Canada  Adults  53  24  RT-PCR  Brandwein  et  al.35
Mexico  Children  59  2.7  FISH  Pérez-Vera  et  al.17
Mexico  Children  2  3.8  RT-PCR  Jiménez-Morales  et  al.18
Chile  Adults  35  5.7  Cytogenetic  Arteaga-Ortíz  et  al.19
Chile  Children  44  2.3  Cytogenetic  Legües  et  al.31
Europe
USA--UK  Adults  1521  19  RT-PCR  Rowe  et  al.14
France  Adolescents  100  6  Cytogenetic  Boissel  et  al.36
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